Australia markets closed

Shandong Boan Biotechnology Co., Ltd. (UJ9.F)

Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
1.1700+0.0100 (+0.86%)
As of 08:59AM CET. Market open.
Full screen
Previous close1.1600
Open1.1700
Bid1.1600 x N/A
Ask1.2300 x N/A
Day's range1.1700 - 1.1700
52-week range1.0800 - 2.2400
Volume67
Avg. volume1
Market cap688.552M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-0.0300
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • PR Newswire

    Boan Biotech's Two Innovative Drugs Targeting Claudin 18.2 Granted ODD by FDA

    Boan Biotech today announced that two of its Claudin18.2-targeted investigational drugs have been granted the Orphan Drug Designation (ODD) for the treatment of pancreatic cancer by the U.S. Food and Drug Administration (FDA): one is BA1105, an innovative antibody; and the other is BA1301, an innovative Antibody-Drug Conjugate (ADC).

  • PR Newswire

    First Patient Enrolled in Phase III Clinical Trial of Boan Biotech's Nivolumab Injection

    Boan Biotech (6955.HK) announced today that the first patient in Phase III clinical trial of its Nivolumab Injection (BA1104) in China has been enrolled. BA1104 is the first biosimilar to Opdivo® to undergo a Phase III study in China.

  • PR Newswire

    Boan Biotech's BA1202 Approved for Clinical Trial

    Boan Biotech announced today that its BA1202, a CEACAM5 (CEA)/CD3 bispecific antibody, has been approved for a clinical trial by the Center for Drug Evaluation of China's National Medical Products Administration (NMPA). BA1202 is the first CEA/CD3 bispecific antibody approved for a clinical trial in China.